Search

Your search keyword '"Hudis, Clifford"' showing total 3 results
Start Over Author "Hudis, Clifford" Topic trastuzumab Publisher new england journal of medicine
3 results on '"Hudis, Clifford"'

1. Trastuzumab — Mechanism of Action and Use in Clinical Practice.

Author

Hudis, Clifford A.

Subjects
*BREAST cancer treatment, *TRASTUZUMAB, *MONOCLONAL antibodies, *DRUG therapy, *GROWTH factors, *CELL proliferation, *CELL growth, *CLINICAL medicine, *CLINICAL trial registries, *PREVENTION, *THERAPEUTICS
Abstract

This article presents a review of the breast cancer medication trastuzumab, its mechanism of action and clinical value. In general, patients with breast-cancer cells that overexpress human epidermal growth factor receptor type 2 (HER2) have decreased overall survival and may have differential responses to treatment. Trastuzumab works by binding to the domain of HER2 and inhibiting the proliferation and survival of HER2-dependent tumors. Many studies of the drug are outlined. The most pivotal of all showed that the activity of trastuzumab in combination with chemotherapy was more effective than chemotherapy alone.

Published
2007
Full Text
View/download PDF

2. Trastuzumab — Mechanism of Action and Use.

Author

Hudis, Clifford A.

Subjects
*LETTERS to the editor, *TRASTUZUMAB
Abstract

A reply by Clifford A. Hudis to letters to the editor about his article “Trastuzumab — mechanism of action and use in clinical practice” in the July 5, 2007 issue is presented.

Published
2007
Full Text
View/download PDF

3. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

Author

Tolaney, Sara M., Barry, William T., Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth A., Partridge, Ann H., Hao Guo, Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., and Winer, Eric P.

Subjects
*BREAST cancer treatment, *PACLITAXEL, *TRASTUZUMAB, *ADJUVANT treatment of cancer, *HER2 protein, *CANCER relapse, *DRUG side effects, *DRUG efficacy
Abstract

The article discusses a study which examined the treatment of human epidermal growth factor receptor type 2 (HER2)-positive breast cancer using adjuvant paclitaxel and trastuzumab. Topics discussed include the risk of early cancer recurrence, effectiveness and adverse events associated with the adjuvant therapy, and the rate of survival free from the disease.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results